At Scantox Group, we are dedicated to advancing biomedical research by providing innovative preclinical solutions. We understand the unique challenges of bringing new therapies to the market. With our passion for scientific exploration, we are committed to provide comprehensive and tailored solutions that drive successful drug development programs.
We have a relentless pursuit of knowledge, utilizing state-of-the-art technologies and advanced methodologies in our laboratories to deliver high-quality data and insights. Through our collaborative approach, we foster innovation by combining expertise from various disciplines.
Find below a list of our current R&D efforts. If you are interested in collaborating on any of these projects, just contact us to discuss details!
Pipeline
Our collaboration efforts are particularly geared towards, but not limited to, the following areas:
- Neurology
- Rare diseases
- Metabolic Disorder
- Immunology
In addition to shown projects, we have several programs that are continuously performed:
- Program for biomarkers
- Establishment and characterization of new cell systems
- Development and evaluation of behavioral test protocols
- Establishment of new surgery/treatment techniques
| Project | Status | |
|---|---|---|
| Psychiatric diseases |  | |
 | Depression model |  |
| Anxiety model |  |
 | Psychodelics in vitro |  |
| Aging | ||
| Induced senescence model |  |
| Accelerated senescence model | |
| In vitro senescence in complex models (cerebral organoids) |  |
| Pain | ||
| Nitroglycerin-Induced Migraine Mouse Model |  |
| Pain in vitro model based on sensory neurons | |
| Parkinson's Disease | ||
| Alpha-synuclein seeding in a transgenic PD mouse model |  |
| AAV-A53T induced PD model | |
| Intrastriatal Rotenone-Induced Mouse Model | |
| Peripheral administration of toxin | |
| Characterization iPSC-derived PD lines |  |
| Alzheimer’s Disease | ||
| Characterization of a double transgenic mouse model | |
| Tau seeding in transgenic AD mouse model | |
| Effect of environmental factors on the AD phenotype | |
| PS19 Transgenic Mouse Model | |
| Establishment of AD-relevant organoid models | |
| Multiple Sclerosis | ||
| Cuprizone-Induced multiple sclerosis | |
| De- and remyelinization in organotypic cerebellar slices |  |
| Amyotrophic lateral sclerosis | ||
| Effect of using different administration routes in TDP-43-induced model |  |
| TDP-43-Induced ALS Mouse Model | |
| Characterization of B6.SOD1-G93A mice | |
| iPSC-derived motor neuron-based in vitro screening platform | |
| LSDs | ||
| Characterization of fibroblasts from LSD Patients (Krabbe, Fabry and more) | |
| Methods | ||
| MRI imaging in rodents of various indications through partnership | |
Invitation for Collaboration
Join us in our quest to advance preclinical research and make meaningful contributions. Our primary focus is addressing unmet needs in translational research and bridging existing gaps in disease modeling.
Please contact us to discuss potential collaboration projects.
Selection of Our Recent and Previous Collaborations
- Drug Repurposing for Effective Alzheimer’s Medicines study, Women’s Hospital and Harvard Medical School, Boston, MA, USA
- Effect of hydrochloroquine on Alzheimer’s disease phenotypes, National Institute of Health, Baltimore, MD, USA
- Brain proteomic signature of Alzheimer’s disease patients with ApoEε4 mutation, National Institute of Health, Baltimore, MD, USA
- Development and characterization of bispecific tau antibodies binding to C1q or α-synuclein, Maptimmune, The Hage, The Netherlands
- Mouse models of autism spectrum disorder, University of Graz, Austria
- Anti-pyroglutamate-3 Aβ antibodies affect cognition in Alzheimer’s disease mouse model, Vivoryon Therapeutics AG, Halle (Saale), Germany
- Retromer function in Niemann-Pick Type C disease, Ruder Boskovic Institute, Zagreb, Croatia
- Leukotriene receptor antagonist montelukast for the treatment of Alzheimer’s disease, Paracelsus Medical University, Salzburg, Austria
- Phosphorylation profile of tau in the brain of AD patients, Newcastle University, Newcastle upon Tyne, UK
- Metabolic phenotyping of an Alzheimer’s disease mouse model, Medical University of Graz, Austria
- In vivo imaging of an Alzheimer’s disease rat model, Austian Institute of Technology, Austria
- Characterization of a Huntington disease rat model, University of Tübingen, Germany
- Influence of β-synuclein on Alzheimer’s disease pathology, Medical University of Graz, Austria
- External quality control program for CSF biomarkers, Alzheimer’s Association